Voyager Therapeutics (VYGR) Enterprise Value (2014 - 2026)
Voyager Therapeutics (VYGR) reported Enterprise Value of -$141.5 million for Q1 2026, up 40.06% on a YoY basis from -$101.0 million in Q1 2025, and up 27.98% sequentially from -$196.4 million in Q4 2025.
Voyager Therapeutics (VYGR) Enterprise Value (2014 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 13 years of Enterprise Value data on file, last reported at -$141.5 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 40.06% year-over-year to -$141.5 million; the trailing twelve-month figure through Mar 2026 stood at -$141.5 million (up 40.06% YoY), and the FY2025 full-year result was -$196.4 million, up 26.34% from the prior year.
- Enterprise Value advanced to -$141.5 million in Q1 2026, from -$196.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$118.8 million in Q4 2022 to a low of -$399.6 million in Q1 2024.
- A 5-year average of -$233.9 million and a median of -$230.9 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value plunged 94.26% in 2023 and surged 41.89% in 2025, its largest moves.
- Tracing VYGR's Enterprise Value over 5 years: stood at -$118.8 million in 2022, then sank by 94.26% to -$230.9 million in 2023, then slipped by 15.51% to -$266.7 million in 2024, then rose by 26.34% to -$196.4 million in 2025, then gained by 27.98% to -$141.5 million in 2026.
- Business Quant data shows VYGR's Enterprise Value at -$141.5 million in Q1 2026, -$196.4 million in Q4 2025, and -$208.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Voyager Therapeutics | 184.74 Mn | 43.26 Mn | - | -141.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -141.48 Mn |
| Dec 31, 2025 | -196.45 Mn |
| Sep 30, 2025 | -208.93 Mn |
| Jun 30, 2025 | -215.59 Mn |
| Mar 31, 2025 | -236.02 Mn |
| Dec 31, 2024 | -266.68 Mn |
| Sep 30, 2024 | -345.36 Mn |
| Jun 30, 2024 | -371.02 Mn |
| Mar 31, 2024 | -399.57 Mn |
| Dec 31, 2023 | -230.88 Mn |
| Sep 30, 2023 | -252.94 Mn |
| Jun 30, 2023 | -272.75 Mn |
| Mar 31, 2023 | -273.31 Mn |
| Dec 31, 2022 | -118.85 Mn |
| Sep 30, 2022 | -131.64 Mn |
| Jun 30, 2022 | -148.06 Mn |
| Mar 31, 2022 | -166.83 Mn |
| Dec 31, 2021 | -132.54 Mn |
| Sep 30, 2021 | -121.50 Mn |
| Jun 30, 2021 | -142.98 Mn |